Anti-tumor polyphyllin liposome
Through the liposome delivery technology of load-loaded saponins, the problem of poor efficacy of anti-tumor drugs in CSC treatment was solved, significantly improved anti-tumor selectivity and efficacy, and provided new therapeutic strategies by targeting RAN proteins.
Patent Information
- Application Number
- CN202411268517.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-11-08
AI Technical Summary
Existing anti-tumor drugs are not effective in treating tumor stem-like cells (CSCs), and chemotherapy can lead to CSC enrichment, increasing tumor resistance and risk of recurrence.
The Chonglou saponin liposome is used to carry insoluble Chonglou saponin I (PPII), and the liposome delivery technology is used to deliver it to the cells to avoid direct effects with the cell membrane, reduce toxicity to normal cells, and improve anti-tumor Selective.
It significantly improves the anti-CSC activity of Chonglou saponin, reduces the toxicity to normal cells, enhances the anti-tumor efficacy, and provides a new therapeutic strategy by discovering RAN protein as a target, improving the selectivity and therapeutic effect of CSCs.
Smart Images

Figure CN118903433A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a Paris polyphylla saponin liposome that resists tumor stem cells. Background Art
[0002] With the continuous progress of drug research and development and technological innovation, more and more anti-tumor drugs are used in cancer treatment, including traditional cytotoxic chemotherapy drugs, molecular targeted drugs targeting specific molecular mechanisms, and innovative immunotherapy drugs. However, drug resistance remains one of the great challenges in tumor treatment, leading to treatment failure and tumor recurrence. Cancer stem-like cells (CSCs), also known as tumor-initiating cells, are characterized by high self-renewal and tumorigenic potential, and are key contributors to tumor resistance, heterogeneity, and epithelial-mesenchymal transition. CSCs are particularly common in highly invasive malignant tumors with poor prognosis and high risk of recurrence, such as triple-negative breast cancer (TNBC), pancreatic cancer, and glioblastoma. As the main method of cancer treatment, traditional chemotherapy drugs can usually effectively kill rapidly dividing ordinary cancer cells, but are ineffective against CSCs in a dormant state of division. What is more serious is that chemotherapy is not only difficult to kill CSCs, but will cause the enrichment of CSCs, resulting in an increase in the "stemness" of tumors.
[0003] Targeted elimination of CSC therapeutic strategies aims to eliminate these tumorigenic cells, leading to tumor regression and inhibiting tumor recurrence. Currently, dozens of CSC-targeted drugs have entered clinical trials. Drug discovery is a complex and lengthy process involving multiple stages and technologies, including structural innovation and optimization of existing drugs, computer-aided drug design (CADD), combination drug development, high-throughput screening (HTS), and artificial intelligence (AI) technology, which has received increasing attention in recent years. In the discovery and development of existing or available drug molecules with new pharmacological indications, drug repurposing remains a viable alternative that can reduce development costs, shorten development time, and reduce the risk of failure. In the process of modern new drug development, natural products are still an important source of lead compounds and new drug development. They play an important role in drug therapy, especially in cancer treatment, and also promote the discovery and development of natural products targeting CSC. Therefore, the development of natural products targeting CSC elimination brings new hope for drug therapy of tumors. However, natural products have problems such as poor solubility, low stability, poor selectivity, and low bioavailability in terms of drugability. Nano drug delivery system is a method that uses nanotechnology to improve drug delivery. It can increase the solubility of poorly soluble drugs, improve drug stability, improve drug pharmacokinetic behavior and biodistribution in vivo, enhance drug efficacy, and reduce adverse reactions. Among them, liposomes are lipid vesicles composed of phospholipids and cholesterol. They can encapsulate both fat-soluble drugs and water-soluble drugs and have good biocompatibility. More than a dozen liposome drugs have been approved for marketing worldwide, and most of the indications are cancer. Therefore, liposome delivery technology provides new ideas and methods for improving the drugability of natural products, increasing efficacy and reducing toxicity. Summary of the invention
[0004] One of the purposes of the present invention is to provide the use of RAN protein inhibitor in the preparation of drugs for treating tumor stem cell-related drug-resistant tumors.
[0005] Furthermore, the RAN protein inhibitor is one or more of small molecule compounds, proteins, polypeptides, polysaccharides, glycoproteins, glycopeptides or nucleic acids.
[0006] Furthermore, the tumor stem-like cell-related drug-resistant tumor is triple-negative breast cancer, liver cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, lung cancer or osteosarcoma.
[0007] Another object of the present invention is to provide the use of Paris polyphylla saponin liposomes in the preparation of drugs for treating drug-resistant tumors associated with tumor stem cells.
[0008] Furthermore, the tumor stem-like cell-related drug-resistant tumor is triple-negative breast cancer, liver cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, lung cancer or osteosarcoma.
[0009] Furthermore, the Paris polyphylla saponin liposome is made of Paris polyphylla saponin, phospholipids, cholesterol and DSPE-PEG; the mass of Paris polyphylla saponin is 1%-10% of the total mass of phospholipids, cholesterol and DSPE-PEG; the molar percentage of phospholipids is 30%-80%, the molar percentage of cholesterol is 15%-60%, the molar percentage of DSPE-PEG is 1%-15%, and the sum of the molar percentages of the three is 100%.
[0010] Furthermore, the phospholipid is phosphatidylcholine, hydrogenated phosphatidylcholine, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), 1-palmitoyl-2-oleoylphosphatidylcholine (POPC), dipalmitoylphosphatidylglycerol (DPPG) or dimyristoylphosphatidylglycerol (DMPG).
[0011] Furthermore, the paris saponin is paris saponin I (PPI), paris saponin II (PPII) or paris saponin III (PPIII).
[0012] In the present invention, the Paris polyphylla saponin liposomes can be prepared by conventional liposome preparation methods, such as ethanol injection method, thin film dispersion method, and the like.
[0013] In one embodiment of the present invention, the preparation process of the Paris polyphylla saponin liposomes is as follows: phospholipids, cholesterol, DSPE-PEG and Paris polyphylla saponin (PPI, PPII or PPIII) are dissolved in anhydrous ethanol, then added to PBS, and after removing the ethanol, ultrasonic or homogenous dispersion is performed, and the drug-loaded liposomes are obtained after passing through a membrane.
[0014] In view of the problem that existing common chemotherapy drugs have poor therapeutic effects on tumor stem cell-related drug-resistant tumors, the inventors screened the natural product monomer compound library in the early stage to find monomer compounds that have inhibitory effects on chemotherapy-resistant CSC-enriched drug-resistant tumor cell models. After screening and experiments, it was found that the main steroidal saponin component in Paris polyphylla - Paris polyphylla saponin (PP) can produce effective cytotoxicity to CSC-rich TNBC cells. Among them, among the natural product monomers Paris polyphylla saponin I (PPI), Paris polyphylla saponin II (PPII), Paris polyphylla saponin III (PPIII), Paris polyphylla saponin V (PPV), Paris polyphylla saponin VI (PPVI), Paris polyphylla saponin VII (PPVII), Paris polyphylla saponin H (PPH), PPI, PPII, and PPIII have strong proliferation inhibitory effects on CSC-rich TNBC cells, and PPII shows the strongest cell proliferation inhibitory effect on CSC-rich TNBC cells. Therefore, PPI, PPII, and PPIII can be used for the treatment of tumor stem cell-related drug-resistant tumors. However, in addition to its poor water solubility, PPII has a strong destructive effect on biological membranes such as cell membranes due to its amphiphilic surfactant-like chemical structure, which leads to its strong cell proliferation inhibitory activity on CSC and strong cytotoxicity to normal cells, resulting in poor selectivity and poor drugability of PPII against CSC. In view of this, the inventors designed and adopted the most applicable liposome delivery technology to encapsulate poorly soluble PPII to prepare PPII liposomes (PPII / L); PPII / L can avoid direct interaction between PPII and the outer membrane of the cell membrane, deliver PPII into the cell, and release PPII inside the cell; PPII / L not only retains the anti-CSC activity of PPII, but also greatly reduces its toxicity to normal cells, significantly improves the anti-tumor selectivity and therapeutic window of PPII, and exerts a synergistic and toxic reduction effect. At the same time, the inventors used molecular biological techniques to discover and verify that RAN protein is the target of PPII's anti-CSC action, which also provides new inspiration for the future development of tumor stem cell-related drug-resistant tumor treatment drugs with RAN protein as the target. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 is the cell survival rate of 4T1 TCs in Example 1 after being treated with 446 natural products.
[0016] Figure 2 This is the cell survival rate of 4T1 TCs in Example 1 after being treated with different PP-based natural products.
[0017] Figure 3 This is the cell survival rate of different TNBC and liver cancer TCs in Example 1 after treatment with PPI, PPII, and PPIII.
[0018] Figure 4It is the cell survival rate of SUM159PT SCs after being treated with PPI, PPII and PPIII in Example 1.
[0019] Figure 5 The cell survival rates of the three normal cell models in Example 1 after being treated with PPI, PPII, and PPIII.
[0020] Figure 6 This is a transmission electron microscope photo of PPI / L, PPII / L, and PPIII / L in Example 2.
[0021] Figure 7 This is the in vitro release curve of PPI / L, PPII / L, and PPIII / L in Example 2.
[0022] Figure 8 This is an evaluation of the hemolytic effect of PPI, PPII, and PPIII on red blood cells in Example 2.
[0023] Fig. 9 This is an evaluation of the hemolytic effect of PPI / L, PPII / L, and PPIII / L on red blood cells in Example 2.
[0024] Fig.10 This is the cell survival rate of different TNBC and liver cancer TCs in Example 2 after treatment with PPI / L, PPII / L, and PPIII / L.
[0025] Fig.11 It is the cell survival rate of SUM159PT SCs in Example 2 after being treated with PPI / L, PPII / L, and PPIII / L.
[0026] Fig.12 The cell survival rate of SUM159PT TCs and SUM159PT SCs in Example 2 after being treated with PTX / L and DOX / L.
[0027] Fig.13 The cell survival rates of the three normal cell models in Example 2 after being treated with PPI / L, PPII / L, and PPIII / L.
[0028] Fig.14 The figure shows the change in the number of 4T1 tumor spheres after being treated with different liposomes in Example 2.
[0029] Fig.15 The expression of intracellular Sox2, Oct4 and Nanog in 4T1 TCs after treatment with different liposomes in Example 2.
[0030] Fig.16These are photos of major organs and HE-stained sections of lung tissue of healthy mice after single administration of PPI, PPII, PPIII (a) and PPI / L, PPII / L, PPIII / L (b) in Example 3.
[0031] Fig.17 The expression of Sox2 and Nanog in tumor tissues of tumor-bearing mice inoculated with 4T1 TCs in Example 3 after treatment with different liposomes, (a) immunohistochemical staining sections of tumor tissues, (b) quantitative relative expression levels compared with the saline group.
[0032] Fig.18 The tumor-bearing mice (~0.1 cm) inoculated with 4T1 TCs in Example 3 3 Tumor volume) Therapeutic effect evaluation after treatment with different liposomes, (a) tumor volume change, (b) tumor mass, (c) tumor photo, (d) tumor inhibition rate, (e) HE staining section of tumor tissue.
[0033] Fig.19 The tumor-bearing mice (~0.1 cm) inoculated with 4T1 TCs in Example 3 3 Tumor volume) Evaluation of the therapeutic effect after treatment with PPII and different doses of PPII / L, (a) change of tumor volume, (b) tumor inhibition rate, (c) tumor photo, (d) HE staining section of tumor tissue.
[0034] Fig. 20 The tumor-bearing mice (~0.5 cm) inoculated with 4T1 TCs in Example 3 3 Tumor volume) Therapeutic evaluation after treatment with PTX / L and different doses of PPII / L, (a) tumor volume change, (b) tumor mass, (c) tumor photos.
[0035] Fig.21 This is the evaluation of the therapeutic effects of different liposomes after tumor resection in tumor-bearing mice inoculated with 4T1-Luc TCs in Example 3, (a) mouse IVIS imaging pictures, (b) changes in the volume of each tumor, (c) changes in the average tumor volume, and (d) mouse survival.
[0036] Fig. 22 This is the efficacy evaluation of the mouse tumor metastasis model after intravenous injection of 4T1-Luc TCs in Example 3 and treatment with different liposomes, (a) mouse IVIS imaging image, (b) bioluminescence intensity changes.
[0037] Fig.23 This is the evaluation of the therapeutic efficacy of different liposomes in the mouse tumor metastasis model after intravenous injection of 4T1-Luc TCs in Example 3, (a) Bouin staining photos of lung tissue, (b) the number of tumors in lung tissue.
[0038] Fig.24 This is the evaluation of the therapeutic efficacy of different liposomes in the mouse tumor metastasis model after intravenous injection of 4T1-Luc TCs in Example 3, (a) HE staining section of lung tissue, (b) immunohistochemical staining section of tumor in lung tissue.
[0039] Fig.25 The survival time of the mouse tumor metastasis model injected intravenously with 4T1-Luc TCs in Example 3 after treatment with different liposomes.
[0040] Fig.26 This is the target for screening the anti-CSC effect of PPII by the LiP-SMap method in Example 4.
[0041] Fig. 27 The survival rate of SUM159PT SCs in Example 4 after being treated with different siRNAs.
[0042] Fig.28 The expression of Nanog, Oct4 and CD49f in SUM159PT SCs treated with different liposomes in Example 4 + Percentage of cell population.
[0043] Fig.29 The dissociation constant between RAN protein and PPII was determined by SPR-based BIAcore in Example 4.
[0044] Fig.30 This is the molecular simulation docking of RAN protein and PPII in Example 4.
[0045] Fig.31 This is the efficacy evaluation of tumor-bearing mice inoculated with shNC / SUM159PT SCs and shRAN / SUM159PT SCs after PPII / L treatment in Example 4, (a) tumor volume change, (b) tumor photo, (c) tumor mass.
[0046] Fig.32 These are immunohistochemical staining sections of tumor tissues of tumor-bearing mice inoculated with shNC / SUM159PT SCs and shRAN / SUM159PT SCs in Example 4 after being treated with PPII / L.
[0047] Fig.33 This is the correlation analysis between the expression of RAN protein and the malignancy of breast cancer in Example 4, (a) immunohistochemical staining sections of cancerous tissue and adjacent tissue of breast cancer patients, (b) relative expression of RAN protein in cancerous tissue of breast cancer patients to adjacent tissue. DETAILED DESCRIPTION
[0048] The preferred embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that the following examples are provided only for the purpose of illustration and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.
[0049] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0050] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0051] Example 1
[0052] Screening of anti-CSC natural products
[0053] 1. Compound library screening
[0054] 1. Discovery of PP
[0055] A CSC-rich cell model was obtained by serum-free suspension cell culture. Specifically, adherent cells were inoculated in ultra-low adhesion culture dishes and cultured in serum-free medium containing B27 additive (1×), epidermal growth factor (20 ng / mL), basic fibroblast growth factor (20 ng / mL) and insulin (5 μg / mL). The culture dishes were placed in a three-gas incubator and cultured under hypoxic conditions. Under this condition, the cells formed multicellular tumor spheres rich in CSC cell populations.
[0056] CCK-8 cell proliferation and toxicity assay was used to determine the inhibitory effect of natural products in the existing natural product monomer compound library on cell proliferation. CSC-rich mouse TNBC 4T1 tumor sphere cells (TCs) (8×10 3 Cells / well) were placed in a 96-well cell plate and incubated with 446 natural products (0.5 μM) in the compound library for 24 hours, and then incubated with CCK-8 for 4 hours. The absorbance was measured at 450 nm using an ELISA reader to calculate cell viability.
[0057] The results are as follows Figure 1 As shown, PPII had the strongest inhibitory effect on the proliferation of 4T1 TCs among 446 natural products, and the survival rate of 4T1 TCs was less than 25% at the same concentration and treatment time.
[0058] 2. Screening of PP-based natural products
[0059] The above-mentioned CCK-8 method was used to investigate the inhibitory effects of PP natural products PPI, PPII, PPIII, PPV, PPVI, PPVII, and PPH on the proliferation of 4T1TCs.
[0060] The results are as follows Figure 2 As shown in Figure 2, PPI, PPII, and PPIII have strong inhibitory effects on the proliferation of 4T1 TCs, with a half inhibitory concentration (IC 50 ) were 156nM (PPI), 89nM (PPII), and 312nM (PPIII), among which the IC 50 The lowest, indicating that it has the strongest cell proliferation inhibitory effect.
[0061] 2. Inhibitory effect of PP on CSC proliferation
[0062] 1. Inhibitory effect on proliferation of TCs of triple-negative breast cancer and liver cancer
[0063] The above-mentioned CCK-8 method was used to investigate the proliferation inhibitory effects of PPI, PPII, and PPIII on TCs of various human triple-negative breast cancers and liver cancers that are rich in CSCs.
[0064] The results are as follows Figure 3 As shown in the figure, PPI, PPII, and PPIII have strong inhibitory effects on the proliferation of TCs of human triple-negative breast cancer SUM159PT, HCC1937, and HCC70, and human liver cancer Hepa1-6, HepG2, and Huh-7. 50 They are SUM159PTTCs: 196nM (PPI), 106nM (PPII), 471nM (PPIII); HCC1937 TCs: 207nM (PPI), 170nM (PPII), 476nM (PPIII); HCC70 TCs: 251nM (PPI), 110nM (PPII), 418nM (PPIII); Hepa1-6 TCs: 119nM (PPI), 101nM (PPII), 246nM (PPIII); HepG2 TCs: 222nM (PPI), 88nM (PPII), 388nM (PPIII); Huh-7 TCs: 226nM (PPI), 159nM (PPII), 403nM (PPIII), among which the IC of PPII 50 The lowest, indicating that it has the strongest cell proliferation inhibitory effect.
[0065] 2. Proliferation inhibition of triple-negative breast cancer sorted cells (SCs)
[0066] Flow cytometry was used to obtain CD44 cells with a higher degree of stemness enrichment. + CD24 - CD49f +SUM159PT SCs. The formed SUM159PT tumor spheres were digested into single cells and labeled with APC-CD44, PE-CD24 and FITC-CD49f fluorescent labeled antibodies. After washing with PBS three times, the cells were filtered with a cell filter (pore size 40 μm) and sorted by flow cytometry to obtain CD44 + CD24 - CD49f + SUM159PT SCs. The proliferation inhibitory effects of PPI, PPII and PPIII on the cells were further investigated using the CCK-8 method as described above.
[0067] The results are as follows Figure 4 As shown in Figure 2, PPI, PPII, and PPIII still have a strong inhibitory effect on the proliferation of SUM159PT SCs with a higher degree of stemness enrichment. 50 281nM (PPI), 138nM (PPII), 643nM (PPIII), among which the IC 50 The lowest, indicating that it has the strongest cell proliferation inhibitory effect.
[0068] 3. Toxicity of PP to Normal Cells
[0069] The cytotoxicity of PPI, PPII, and PPIII on human mammary epithelial cells MCF-10A, human hepatocytes L-02, and mouse primary neutrophils (NEs) was investigated using the above-mentioned CCK-8 method.
[0070] The results are as follows Figure 5 As shown, PPI, PPII, and PPIII have strong cytotoxicity to the three normal cell models. When the concentration is higher than 0.5 μM, the survival rate of the three normal cells is less than 50%, and when the concentration is 1 μM, the survival rate of the three normal cells is less than 25%. The results show that although PPI, PPII, and PPIII have strong proliferation inhibition effects on CSCs, they also have strong cytotoxicity to normal cells and have poor selectivity against CSCs.
[0071] Example 2
[0072] Preparation and characterization of PP liposomes and evaluation of their anti-CSC activity in vitro
[0073] 1. Preparation and characterization of PP liposomes
[0074] 1. Preparation of drug-loaded liposomes
[0075] The drug-loaded liposomes were prepared by ethanol injection method. Phosphatidylcholine, cholesterol, DSPE-PEG and PP (PPI, PPII or PPIII) were dissolved in anhydrous ethanol at a mass ratio of 5:1:1:0.25 (molar percentage: ~69.2% phosphatidylcholine, ~27.1% cholesterol, ~3.7% DSPE-PEG), and then added to PBS. After removing the ethanol, the drug-loaded liposomes were obtained by ultrasonic or homogenization dispersion and membrane (220nm): PPI liposomes (PPI / L), PPII liposomes (PPII / L) and PPIII liposomes (PPIII / L).
[0076] 2. Characterization of Drug-loaded Liposomes
[0077] The particle size and potential of the liposomes were measured using a particle size potentiometer, and the encapsulation efficiency and drug loading of the liposomes were measured. The results are shown in Table 1. The particle sizes of PPI / L, PPII / L, and PPIII / L were all about 80 nm, the encapsulation efficiency was greater than 90%, and the drug loading was about 2%.
[0078] Table 1. Characterization of PP liposomes
[0079]
[0080] The morphology of PPI / L, PPII / L, and PPIII / L was observed using a transmission electron microscope. Figure 6 As shown, the liposomes are spherical in shape and uniform in size, which is similar to their hydrodynamic particle size.
[0081] PPI / L, PPII / L, and PPIII / L were added to dialysis bags with a molecular weight cutoff of 14 kDa, respectively, and immersed in PBS (pH 7.4) containing Tween80 (2%). The concentration of PPI, PPII or PPIII in the release solution was measured at regular intervals, and the in vitro release behavior of PPI / L, PPII / L, and PPIII / L was calculated. The results are shown in Figure 7 As shown, PPI, PPII, and PPIII can be released continuously after being encapsulated in liposomes.
[0082] 3. Characterization of hemolytic properties
[0083] Whole blood was collected from the orbital venous plexus of BALB / c mice (female, 6-8 weeks old) into EDTA pretreated tubes and washed three times by centrifugation with saline (2,500rpm, 5min). 2mL of red blood cell suspension was resuspended in PBS and incubated with different concentrations of PPI, PPII, PPIII, PPI / L, PPII / L, and PPIII / L at 37°C for 1h. After centrifugation (2,500rpm, 5min), the absorbance of the supernatant was measured at 545nm using an ELISA reader. Red blood cells treated with Triton X-100 (1%) were used as a positive control for 100% hemolysis, and the hemolysis rate after different treatments was calculated.
[0084] The results are as follows Figure 8 and 9 As shown in the figure, it is known that hemolysis occurs when the hemolysis rate is greater than 5%. PPI, PPII, and PPIII show obvious hemolysis at a low concentration of 0.5 μM, with hemolysis rates of 23.01%, 58.92%, and 28.16%, respectively. Figure 8 ), while in contrast, PPI / L, PPII / L, and PPIII / L hardly produced hemolysis at a higher concentration of 20 μM, and the hemolysis rates were all less than 5% ( Fig. 9 ). The results showed that liposome encapsulation significantly reduced the hemolytic effect of PP. PP natural products PPI, PPII and PPIII are saponin natural products with a hydrophilic and lipophilic amphiphilic surfactant chemical structure, which leads to the biomembrane-destroying effect of surfactants. Not only will they destroy the red blood cell membrane and cause the adverse effect of hemolysis, but they will also destroy the cell membrane structure of normal cells and cause toxicity to normal cells. This is also the reason why PPI, PPII and PPIII have strong cytotoxicity to MCF-10A, L-02 and NEs normal cells; by liposome delivery technology, the poorly soluble PPI, PPII and PPIII are encapsulated in the lipid bilayer of liposomes, which can effectively shield their membrane-destroying effect.
[0085] 2. Evaluation of the anti-CSC activity of PP liposomes in vitro
[0086] 1. Inhibitory effect on proliferation of TCs of triple-negative breast cancer and liver cancer
[0087] The above-mentioned CCK-8 method was used to investigate the proliferation inhibitory effects of PPI / L, PPII / L, and PPIII / L on 4T1, SUM159PT, Hepa1-6, Huh-7, and HepG2 TCs.
[0088] The results are as follows Fig.10 As shown in the figure, PPI / L, PPII / L, and PPIII / L have strong inhibitory effects on the proliferation of TCs of 4T1, SUM159PT, Hepa1-6, Huh-7, and HepG2.50 They are 4T1 TCs: 328nM (PPI / L), 204nM (PPII / L), 787nM (PPIII / L); SUM159PT TCs: 312nM (PPI / L), 181nM (PPII / L), 900nM (PPIII / L); Hepa1-6 TCs: 185nM (PPI / L), 124nM (PPII / L), 316nM (PPIII / L); HepG2 TCs: 267nM (PPI / L), 124nM (PPII / L), 418nM (PPIII / L); Huh-7 TCs: 292nM(PPI / L), 218nM(PPII / L), 699nM(PPIII / L), among which the IC of PPII / L 50 The results showed that liposome delivery technology did not significantly affect the inhibitory effect of PP on CSC proliferation, and the obtained PPI / L, PPII / L and PPIII / L still had strong anti-CSC activity.
[0089] 2. Inhibitory effect on proliferation of SCs in triple-negative breast cancer
[0090] The above-mentioned CCK-8 method was used to investigate the inhibitory effects of PPI / L, PPII / L, and PPIII / L on the proliferation of SUM159PT SCs.
[0091] The results are as follows Fig.11 As shown in Figure 2, PPI / L, PPII / L, and PPIII / L still have a strong inhibitory effect on the proliferation of SUM159PT SCs with a higher degree of stemness enrichment. 50 They are 511nM (PPI / L), 359nM (PPII / L), and 907nM (PPIII / L), respectively. The IC 50 The lowest, indicating that it has the strongest cell proliferation inhibitory effect.
[0092] 3. Comparison with commonly used anti-tumor liposome drugs in clinical practice
[0093] Preparation of paclitaxel liposomes (PTX / L): PTX / L was prepared by the thin film method. Phospholipids, cholesterol, DSPE-PEG and PTX were dissolved in chloroform at a mass ratio of 5:1:1:0.25, and vacuum dried for 10 min at 37°C using a rotary evaporator to form a thin lipid film. After removing the residual organic solvent under reduced pressure in a constant temperature vacuum drying oven, PBS was added to hydrate the thin film, and ultrasonic or homogenized dispersion was used to obtain PTX / L after passing through a membrane (220 nm).
[0094] Preparation of doxorubicin liposomes (DOX / L): DOX / L was prepared by the ammonium sulfate gradient method. Phospholipids, cholesterol, and DSPE-PEG were dissolved in chloroform at a mass ratio of 5:1:1, and vacuum dried at 37°C for 10 minutes using a rotary evaporator to form a thin lipid film. After removing the residual organic solvent under reduced pressure in a constant temperature vacuum drying oven, 300mM ammonium sulfate solution was added for hydration. The obtained liposome suspension was added to a dialysis bag (14kDa MWCO) and dialyzed for 12 hours. 0.25mg / mL of DOX solution was added and stirred in a 45°C water bath for 1 hour. The mixed solution was placed in a 10kDa ultrafiltration tube for ultrafiltration to remove free DOX to obtain DOX / L.
[0095] The above-mentioned CCK-8 method was used to investigate the inhibitory effects of PTX / L and DOX / L on the proliferation of SUM159PT TCs and SUM159PT SCs.
[0096] The results are as follows Fig.12 As shown, the inhibitory effects of PTX / L and DOX / L on the proliferation of SUM159PT TCs and SUM159PT SCs were much lower than those of PPI / L, PPII / L, and PPIII / L.
[0097] 4. Toxicity to normal cells
[0098] The cytotoxicity of PPI / L, PPII / L, and PPIII / L on MCF-10A, L-02, and NEs was investigated using the CCK-8 method described above.
[0099] The results are as follows Fig.13 As shown in the figure, within the concentration range of 0.1μM to 5μM, PPI / L, PPII / L, and PPIII / L were almost non-toxic to the three normal cells, and at a high concentration of 5μM, the cell survival rate was higher than 85%. The results show that liposome delivery can significantly reduce the toxicity of PPI, PPII, and PPIII to normal cells, maintain their anti-CSC activity, and greatly improve their anti-tumor selectivity.
[0100] 5. Inhibition of in vitro tumorigenesis
[0101] CSC-rich 4T1 tumor spheres (diameter > 50 μm) were seeded in a 96-well ultra-low adhesion plate at a cell density of 60 tumor spheres / well and co-incubated with different liposomes (PTX / L, DOX / L, PPI / L, PPII / L and PPIII / L) at a concentration of 2 μM under hypoxic conditions, and the number of tumor spheres with a diameter > 50 μm was recorded.
[0102] The results are as follows Fig.14The destructive effects of PPI / L, PPII / L, and PPIII / L on tumor spheres increased in a time-dependent manner. As the incubation time increased, the number of tumor spheres decreased, among which PPII / L had the strongest effect. However, the destructive effects of PTX / L and DOX / L on tumor spheres were weak.
[0103] 6. Effects on stemness-related transcription factors
[0104] 4T1 TCs (5×10 5 The cells were placed in 6-well ultra-low adhesion plates and incubated with different liposomes (PTX / L, DOX / L, PPI / L, PPII / L and PPIII / L) at a concentration of 0.2 μM for 24 h. The expressions of intracellular stemness-related transcription factors Sox2, Oct4 and Nanog were determined by fluorescent antibody staining and flow cytometry.
[0105] The results are as follows Fig.15 As shown in the figure, compared with PTX / L and DOX / L, PPI / L, PPII / L, and PPIII / L can significantly reduce the expression of stemness-related transcription factors in 4T1TCs. The results showed that PPI / L, PPII / L, and PPIII / L can effectively eliminate CSCs in 4T1TCs, among which PPII / L has the strongest effect.
[0106] Example 3
[0107] In vivo safety and efficacy evaluation of PP liposomes
[0108] 1. In vivo safety evaluation of PP liposomes
[0109] The acute toxicity of free PP and PP liposomes was evaluated by Bliss method. BALB / c mice were intravenously injected with different doses of PPI, PPII, PPIII, PPI / L, PPII / L, and PPIII / L. The mortality rate of mice was monitored within 8 hours, and the median lethal dose (LD 50 The heart, liver, spleen, lung and kidney were collected and photographed, and the lung tissue was histologically examined using hematoxylin-eosin (HE) staining.
[0110] The acute toxicity results are shown in Table 2. The LD values of PPI, PPII, and PPIII for mice after intravenous administration are 50 The values were 1.79μmol / kg, 1.7μmol / kg, and 4.14μmol / kg, respectively, while all mice survived at a high dose of 9μmol / kg for PPI / L, PPII / L, and PPIII / L. Photos of the heart, liver, spleen, lung, and kidney of mice that died after administration of PPI, PPII, and PPIII, as well as the results of HE staining sections of lung tissue are shown in the figure. Fig.16As shown in the figure, the lungs of the death group showed obvious bleeding in the main organs after administration of PPI, PPII, and PPIII, and the presence of a large number of red blood cells in the lung tissue proved that lung damage caused by PPI, PPII, and PPIII was one of the important causes of death in mice. In contrast, no obvious pathological changes were observed in the lung tissues of mice injected intravenously with a high dose of 9 μmol / kg PPI / L, PPII / L, and PPIII / L. The results show that liposome delivery can significantly reduce the in vivo toxicity of PPI, PPII, and PPIII and improve safety.
[0111] Table 2. Acute toxicity
[0112]
[0113] PPI:LD 50 =1.79 μmol / kg(0.808 <LD 50 <2.594,α=0.05)
[0114] PPII:LD 50 =1.732 μmol / kg(1.065 <LD 50 <2.813,α=0.05)
[0115] PPIII:LD 50 =4.14 μmol / kg(2.856 <LD 50 <5.397,α=0.05)
[0116] PPI / L,PPII / L,PPIII / L:LD 50 >9μmol / kg
[0117] PP liposomes inhibit the growth of CSC-rich TNBC orthotopic tumors
[0118] 1. Inhibit the growth of small-volume orthotopic TNBC tumors rich in CSCs
[0119] 4T1 TCs (5×10 5 cells) were inoculated into the mammary fat pad of BALB / c mice. The tumor volume was calculated by length × width. 2 / 2 calculation. For tumor volume of ~0.1cm 3Tumor-bearing mice were intravenously injected with saline, PTX / L (3μmol / kg), DOX / L (3μmol / kg), PPI / L (3μmol / kg), PPII / L (3μmol / kg), and PPIII / L (3μmol / kg), once every other day, for a total of 6 times. Changes in tumor volume were monitored. On the 20th day, the tumor was taken, photographed, weighed, and the tumor inhibition rate was calculated. HE staining was used for histopathological examination of the tumor, and immunohistochemical staining was used to detect the expression of Sox2 and Nanog in the tumor.
[0120] Immunohistochemical results of stemness-related transcription factors Fig.17 As shown in the figure, compared with PTX / L and DOX / L, PPI / L, PPII / L, and PPIII / L can significantly reduce the expression of Sox2 and Nanog in tumor tissues, among which PPII / L has the strongest effect. Fig.18 As shown in the figure, the inhibitory effects of PPI / L, PPII / L, and PPIII / L on mouse tumor growth were significantly higher than those of PTX / L and DOX / L, among which PPII / L had the strongest inhibitory effect on tumor growth. HE staining images of tumor sections showed that large areas of tumor cell death occurred in tumor tissues after treatment with PPI / L, PPII / L, and PPIII / L, among which the PPII / L group had the most dead cells. The results showed that PPI / L, PPII / L, and PPIII / L can efficiently eliminate highly tumorigenic and drug-resistant CSCs, reduce tumor stemness, and thus inhibit the tumor growth of TNBC.
[0121] 2. Dose-dependent inhibition of the growth of small orthotopic tumors of CSC-rich TNBC
[0122] 4T1 TCs (5×10 5 cells) were inoculated into the mammary fat pad of BALB / c mice. 3 Tumor-bearing mice were intravenously injected with normal saline, PPII (1.5 μmol / kg), and three doses of PPII / L (PPII / L(i) (1.5 μmol / kg), PPII / L(ii) (3 μmol / kg), PPII / L(iii) (6 μmol / kg)) every other day for a total of 6 times. The changes in tumor volume were monitored. On the 20th day, the tumor was removed, photographed, weighed, and the tumor inhibition rate was calculated. HE staining was used for histopathological examination of the tumor.
[0123] The results are as follows Fig.19As shown, both PPII and PPII / L have an inhibitory effect on the growth of CSC-rich 4T1 tumors. At the same dose, the tumor inhibitory effect of PPII / L is significantly stronger than that of PPII, and the tumor inhibitory effect of PPII / L is dose-dependent, with the higher the dose, the stronger the inhibitory effect.
[0124] 3. Inhibit the growth of large-volume orthotopic tumors of CSC-rich TNBC
[0125] 4T1 TCs (5×10 5 cells) were inoculated into the mammary fat pad of BALB / c mice. 3 Tumor-bearing mice were intravenously injected with saline, PTX / L (6 μmol / kg), and low, medium, and high doses of PPII / L (PPII / L(i) (3 μmol / kg), PPII / L(ii) (6 μmol / kg), and PPII / L(iii) (9 μmol / kg)), once every other day for a total of 6 times. Changes in tumor volume were monitored. Tumors were harvested on the 12th or 14th day, photographed, and weighed.
[0126] The results are as follows Fig. 20 As shown in the figure, both PTX / L and PPII / L have an inhibitory effect on the growth of large-volume 4T1 tumors rich in CSCs. At the same dose, the tumor inhibitory effect of PPII / L is significantly stronger than that of PTX / L, and the tumor inhibitory effect of PPII / L is dose-dependent, with the higher the dose, the stronger the inhibitory effect. The results show that PPII / L has a strong inhibitory effect on the growth of both small and large-volume TNBC tumors rich in CSCs.
[0127] PP liposomes inhibit postoperative tumor recurrence of CSC-rich TNBC
[0128] Luciferase-labeled 4T1 (4T1-Luc) TCs (5×10 5 cells) were inoculated into the mammary fat pad of BALB / c mice. 3 The tumor-bearing mice underwent surgery to remove the visible tumor, suture the wound and disinfect it with iodine. After that, normal saline, PTX / L (3μmol / kg), DOX / L (3μmol / kg) and PPII / L (3μmol / kg) were injected intravenously once every other day for a total of 6 times. Luciferin sodium salt (120mg / kg) was injected intraperitoneally at the predetermined time, and the mice were imaged using an in vivo imaging system (IVIS), and the changes in tumor volume and the survival of the mice were monitored.
[0129] The results are as follows Fig.21As shown in the figure, the IVIS imaging of mice and the changes in the volume of recurrent tumors all showed that PTX / L, DOX / L and PPII / L all had an inhibitory effect on the postoperative recurrence of CSC-rich 4T1 tumors. In comparison, PPII / L had the strongest inhibitory effect, and the tumor recurrence rate and survival period of mice treated with PPII / L were the lowest. The results showed that PPII / L had a strong inhibitory effect on the postoperative recurrence of CSC-rich TNBC.
[0130] PP liposomes inhibit CSC-rich TNBC metastasis
[0131] 4T1-Luc TCs (2×10 5 cells) were injected intravenously into BALB / c mice. After 7 days, normal saline, PTX / L (3μmol / kg), DOX / L (3μmol / kg), and PPII / L (3μmol / kg) were injected intravenously once every other day for a total of 6 times. Luciferin sodium salt (120mg / kg) was injected intraperitoneally at the predetermined time, and the mice were imaged using IVIS. On the 15th day, lung tissue was obtained, stained with Bouin staining solution, photographed, the number of tumors in the lung tissue was recorded, and the lung tissue was subjected to histopathological examination using HE staining. Immunohistochemical staining was used to detect the expression of Sox2, Nanog, and epithelial cadherin (E-cad) in the tumor. The survival of the mice was monitored.
[0132] The results are as follows Figure 22-25 As shown in the figure, mouse IVIS imaging and fluorescence quantitative data showed that PTX / L, DOX / L and PPII / L all had inhibitory effects on CSC-rich 4T1 tumor metastasis. In comparison, PPII / L had the strongest inhibitory effect ( Fig. 22 ); The results of lung tissue staining and lung tissue tumor counts showed that the number of tumors in the lung tissue of mice treated with PPII / L was the lowest ( Fig.23 ); HE and immunohistochemical staining of lung tissues showed that the number and area of tumors in the lung tissues of mice treated with PPII / L were the smallest. At the same time, compared with PTX / L and DOX / L, PPII / L could significantly reduce the expression of Sox2 and Nanog in lung metastatic tumors and increase the expression of E-cad ( Fig.24 In addition, mice treated with PPII / L had the longest survival ( Fig.25 ). The results showed that PPII / L had a strong inhibitory effect on the metastasis of CSC-rich TNBC.
[0133] Example 4
[0134] Discovery and confirmation of the anti-CSC target of PPII
[0135] 1. Screening of Targets
[0136] The limited hydrolase mass spectrometry (Lip-SMap) method was used to identify potential targets of PPII's anti-CSC effect. Cell lysates of SUM159PT SCs were treated with DMSO or PPII, then digested with proteinase K (PK) and analyzed by mass spectrometry. Fig.26 As shown, seven candidate target proteins were finally selected: RAN, EIF5A, COPE, TKT, MYH9, COPB1 and FSCN1.
[0137] 2. In vitro validation of the target
[0138] 1. Verification of Growth Inhibitory Effect
[0139] SUM159PT SCs were mixed with Lipofectamine TM A mixture of RNAiMAX transfection reagent and small interfering RNA (siRNA) of the target protein was incubated for 48 h, and then incubated with PPII / L (0.2 μM) for 24 h, and then the cell survival rate was determined according to the above-mentioned CCK-8 method.
[0140] Table 3. siRNA sequences
[0141]
[0142] The results are as follows Fig. 27 As shown in the figure, compared with the negative control siRNA (siNC), the cell survival rate of SUM159PT SCs treated with RAN protein siRNA (siRAN) decreased, but after PPII / L treatment, the cell survival rate of SUM159PT SCs did not decrease significantly. The results show that PPII exerts anti-CSC effect by acting on RAN protein, and RAN protein is a potential target of PPII.
[0143] 2. Validation of Inhibition of Stemness-related Protein Expression
[0144] SUM159PT SCs (5×10 5 The cells were placed in a 6-well ultra-low adhesion plate and incubated with 0.2 μM PTX / L, DOX / L and PPII / L for 24 h. TM The mixture of RNAiMAX transfection reagent and siNC or siRAN was incubated for 48 hours. Fluorescent antibody staining and flow cytometry were used to determine the expression of Nanog and Oct4 in cells and CD49f + Percentage of cell population.
[0145] The results are as follows Fig.28 As shown, compared with the siNC group, the expression of Nanog and Oct4 and CD49f in SUM159PT SCs after siRAN treatment was significantly higher than that in the siNC group. + The percentage of cell populations decreased significantly, but there was no significant difference compared with the PPII / L group. The results showed that PPII / L had similar effects to RAN protein knockdown, suggesting that PPII reduces the stemness of CSC-rich TNBC cells by interacting with RAN protein, further proving that RAN protein is a potential target for PPII's anti-CSC effect.
[0146] 3. Verification of affinity between PPII and RAN protein
[0147] The affinity of PPII to RAN protein was analyzed using BIAcore, a bioanalytical sensing technology developed based on surface plasmon resonance (SPR). RAN protein was immobilized on the surface of a CM5 sensor chip, and the actual binding ability of PPII to RAN protein was observed using the BiaCore T200 protein interaction system. For affinity analysis, His-tagged RAN protein was diluted in 10 mM sodium acetate buffer at pH 5.5 and immobilized on a chip with approximately 300 reaction units. PPII was flowed along the chip at different concentrations (0.2, 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25 μM). After each cycle, the sensor surface was regenerated with 10 mM glycine-HCl pH 2.5. Finally, the data were fitted to a 1:1 interactive steady-state binding model using BIAevaluation1.0 software.
[0148] The results are as follows Fig.29 As shown in Figure 2, as the concentration of PPII increases, the response value after binding to RAN protein also increases. The binding force between RAN protein and PPII is expressed by the dissociation constant (K d ) indicates that K is calculated d The value is 1.3 μM. Judging from the affinity level of the protein and small molecule binding, the two have medium to high strength binding, which further illustrates that PPII has the potential for RAN targeted binding.
[0149] 4. Virtual docking analysis of PPII and RAN protein
[0150] Discovery Studio software was used to simulate the binding between PPII and RAN, as well as the hydrogen bonds and amino acids at the binding site: (1) The three-dimensional structure of RAN protein was obtained from the protein database website (5CIQ); (2) the protein was hydrogenated and its multiple conformations were removed, and non-complete amino acid residues were supplemented; (3) Docking: genetic algorithm was used as the docking algorithm for virtual docking; (4) Cluster analysis: visual analysis and display.
[0151] The results are as follows Fig.30 As shown, potential binding pockets around residues GLN-145, TYRP-146, TRP-163, and GLN-205 were identified in the RAN protein. These amino acid residues form hydrogen bonds with PPII and contribute to the binding stability between PPII and RAN.
[0152] 3. In vivo validation of the target
[0153] SUM159PT SCs were transfected with short hairpin RNA (shRNA) (shRAN) of RAN protein (Manufacturer: Public Protein / Plasmid Library) and transferred to medium containing 5 μg / mL puromycin. After culturing for 2 weeks, the culture medium was changed every 3 days until cell spheres were formed. The surviving cell spheres were isolated and cultured in serum-free suspension medium containing 5 μg / mL puromycin. The messenger RNA (mRNA) and protein levels of RAN protein in SUM159PT (shRAN / SUM159PT) SCs treated with shRAN were analyzed separately. SUM159PT SCs or shRAN / SUM159PT SCs (5×10 5 cells) were implanted into the mammary fat pad of NOD / SCID mice. 3 Tumor-bearing mice were intravenously injected with saline and PPII / L (3 μmol / kg) once every other day for a total of 6 times. Changes in tumor volume were monitored. Tumors were harvested on day 18, photographed, and weighed. Immunohistochemical staining was used to detect the expression of Nanog, Oct4, and RAN in tumors.
[0154] The results are as follows Fig.31 and 32 As shown, the tumor growth of mice inoculated with shRAN / SUM159PTSCs was slow compared with that of mice inoculated with SUM159PTSCs ( Fig.31 ), indicating that RAN protein promotes the growth of CSC-rich tumors; in mice inoculated with shRAN / SUM159PT SCs, no significant tumor growth inhibition was observed after PPII / L treatment compared with the saline group ( Fig.31 ), indicating that PPII / L has almost no tumor-suppressing effect on tumors with low expression of RAN protein; immunohistochemical staining sections of tumor tissues showed that the expression of Nanog, Oct4 and RAN in tumor tissues of mice inoculated with SUM159PT SCs was greatly reduced after PPII / L treatment, while the expression of Nanog, Oct4 and RAN in tumor tissues of mice inoculated with shRAN / SUM159PT SCs after PPII / L treatment did not show significant changes ( Fig.32 ). The above results further prove that RAN protein is the target of PPII to exert its anti-CSC effect.
[0155] 4. Correlation analysis between RAN protein expression and malignancy of breast cancer
[0156] Immunohistochemical staining was used to detect the expression of RAN protein in tumor and adjacent tissues of breast cancer patients, and quantitative analysis was performed using Image J software. The 160 breast cancer patients were divided into: (1) adjacent tissues (15) and breast cancer tissues (non-TNBC, 103; TNBC, 42); (2) adjacent tissues (15), grade 1 breast cancer tissues (24), grade 2 breast cancer tissues (70), and grade 3 breast cancer tissues (44).
[0157] The results are as follows Fig.33 As shown in the figure, the expression of RAN protein in TNBC tumor tissue is significantly higher than that in adjacent tissue and non-TNBC tumor tissue. In addition, the expression of RAN protein is positively correlated with the WHO breast cancer grade. The higher the grade of breast cancer (i.e., the higher the malignancy), the higher the expression of RAN protein.
Claims
1. Application of RAN protein inhibitors in the preparation of drugs for treating tumor stem cell-related drug-resistant tumors.
2. The use according to claim 1, characterized in that: The RAN protein inhibitor is one or more of small molecule compounds, proteins, polypeptides, polysaccharides, glycoproteins, glycopeptides or nucleic acids.
3. The use according to claim 1, characterized in that: The tumor stem-like cell-related drug-resistant tumor is triple-negative breast cancer, liver cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, lung cancer or osteosarcoma.
4. Application of Paris polyphylla saponin liposomes in the preparation of drugs for the treatment of drug-resistant tumors associated with tumor stem cells.
5. The use according to claim 4, characterized in that: The tumor stem-like cell-related drug-resistant tumor is triple-negative breast cancer, liver cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, lung cancer or osteosarcoma.
6. The use according to claim 4, characterized in that: The paris saponin liposome is made of paris saponin, phospholipids, cholesterol and DSPE-PEG; the mass of paris saponin is 1%-10% of the total mass of phospholipids, cholesterol and DSPE-PEG; the molar percentage of phospholipids is 30%-80%, the molar percentage of cholesterol is 15%-60%, the molar percentage of DSPE-PEG is 1%-15%, and the sum of the molar percentages of the three is 100%.
7. The use according to claim 6, characterized in that: The phospholipid is phosphatidylcholine, hydrogenated phosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, 1-palmitoyl-2-oleoylphosphatidylcholine, dipalmitoylphosphatidylglycerol or dimyristoylphosphatidylglycerol.
8. The use according to claim 6, characterized in that: The paris saponin is paris saponin I, paris saponin II or paris saponin III.
Citation Information
Patent Citations
Preparation method and application of liposome taking polyphyllin active extract as membrane material
CN115429759A
